Can Measuring Work Functioning Help Identify Meaningful Recovery in Depression?

April 15, 2026

Major depressive disorder (MDD) affects not only mood and emotional well-being but also daily functioning, including a person’s ability to work and maintain productivity. Although symptom improvement is a central goal of depression treatment, understanding whether changes in functioning represent meaningful improvements from a patient’s perspective remains an important challenge.

What is the Lam Employment Absence and Productivity Scale (LEAPS)?

The Lam Employment Absence and Productivity Scale (LEAPS) is a patient-reported measure designed to assess the impact of depression on work-related functioning. Unlike symptom scales that primarily evaluate mood symptoms, LEAPS focuses on how depression affects a person’s ability to perform occupational responsibilities and maintain productivity.

The scale captures different aspects of work impairment, including difficulties with completing tasks, maintaining efficiency, and functioning effectively in a work environment. By measuring functional outcomes directly, LEAPS provides additional information about recovery beyond symptom reduction alone.

A key concept in evaluating clinical outcomes is the minimal clinically important difference (MCID). The MCID represents the smallest change in a measurement score that patients perceive as meaningful improvement. Establishing an MCID helps researchers and clinicians interpret whether changes observed during treatment are likely to reflect meaningful improvements in real-world functioning.

How the Study Worked

This study analyzed data from participants enrolled in the CAN-BIND-1 clinical study, which investigated treatment outcomes in individuals with major depressive disorder.

Researchers examined changes in LEAPS scores over the course of treatment and evaluated how these changes corresponded with meaningful improvements in depressive symptoms and overall functioning. By analyzing patient-reported outcomes, the study aimed to determine the amount of improvement in LEAPS scores that represents a clinically meaningful change.

Establishing an MCID for LEAPS allows future clinical trials and healthcare providers to better understand whether changes in workplace functioning reflect improvements that matter to patients.

“Functional recovery is an important treatment goal in major depressive disorder, as symptom improvement alone may not fully capture the impact of depression on patients’ daily lives, including occupational functioning and productivity.”

What Did This Study Reveal?

The study provided evidence supporting the use of LEAPS as a tool for measuring meaningful changes in work-related functioning among individuals with depression. Key findings included:

  • Changes in LEAPS scores could be interpreted in relation to meaningful improvements in occupational functioning, helping distinguish minor score fluctuations from changes that patients may actually notice in daily life.
  • Establishing an MCID provides clinicians and researchers with a clearer benchmark for evaluating whether treatments improve functional outcomes, rather than relying only on symptom measures.
  • The findings highlight that recovery from depression involves more than reducing sadness or other depressive symptoms; improvements in productivity, work performance, and daily functioning are also important indicators of recovery.
  • Functional outcomes measured through patient-reported tools may complement traditional clinical assessments by capturing aspects of recovery that symptom scales may miss.

Why This Matters

Depression can significantly interfere with employment, productivity, and quality of life. While many clinical studies focus on whether symptoms improve, patients often identify returning to normal activities and functioning as important markers of recovery. By identifying a clinically meaningful threshold for improvement on LEAPS, this study helps strengthen the measurement of functional recovery in depression research. These findings may improve how treatments are evaluated by ensuring that improvements reflect meaningful changes in patients’ everyday lives.

“Traditional measures of depression severity provide important information about symptom changes, but functional outcomes offer additional insight into whether individuals are able to regain meaningful roles and activities affected by illness.”

Limitations to Consider

Although LEAPS provides valuable information about occupational functioning, it is a self-reported measure and may be influenced by individual perceptions, workplace circumstances, and external factors unrelated to depression symptoms. Employment status, workplace environment, job demands, and social factors may also affect productivity outcomes. Additionally, the study population was drawn from the CAN-BIND-1 clinical research cohort, which may limit how broadly the findings apply to all individuals with depression. Further research is needed to confirm the MCID across different populations, occupations, and treatment settings.

Final Takeaway

The findings from this CAN-BIND-1 study help clarify how much improvement on the Lam Employment Absence and Productivity Scale represents a meaningful change for people living with major depressive disorder. By identifying clinically important improvements in work-related functioning, LEAPS may provide a valuable tool for measuring recovery that extends beyond symptom reduction. As depression treatment moves toward more personalized and patient-centred approaches, understanding improvements in real-world functioning will be essential for evaluating whether individuals are truly returning to the activities and roles that matter most to them

Citation: Sachdeva, S., Li, V. W., Chakrabarty, T., Frey, B. N., Hassel, S., Ho, K., Kennedy, S. H., Milev, R., Müller, D. J., Parikh, S. V., Rotzinger, S., Soares, C. N., Taylor, V. H., Uher, R., & Lam, R. W. (2026). Lam Employment Absence and Productivity Scale (Leaps): Analysis of the minimal clinically important difference (Mcid) in patients with major depressive disorder using data from the CAN-BIND-1 study. Journal of Affective Disorders, 403, 121451. https://doi.org/10.1016/j.jad.2026.121451